There has been increasing interest in the Treat-and-Extend model of dosing of intravitreal injections for wet macular degeneration, which aims to reduce the number of visits for patients while individualising treatment frequency depending on disease activity. This latest randomised clinical trial, although studying small numbers of patients, appears to show that this regimen led to similar outcomes when compared with patients receiving an injection every month – except patients on Treat-and-Extend received fewer injections, with almost half of them (45%) having achieved an interval of 8 weeks or more by the end of the first year.
